EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Elucidating Contributions of Drug Transporters/Enzyme to Nonlinear Pharmacokinetics of Grazoprevir by PBPK Modeling With a Cluster Gauss–Newton Method

Takashi Yoshikado iD, Yasunori Aoki iD, Ryo Nakamura, Saeko Shida, Yuichi Sugiyama, Koji Chiba iD

CPT: Pharmacometrics & Systems Pharmacology · 2025-04 · 14 (4) · 770-780

DOI: 10.1002/psp4.13314 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 07.02.2025. Verfasst von Takashi Yoshikado und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Clinical Pharmacology, Yokohama University of Pharmacy, Yokohama, Kanagawa, Japan. Hauptthemen laut MEDLINE: Models, Biological, ATP Binding Cassette Transporter, Subfamily B, Member 1, Cytochrome P-450 CYP3A, Antiviral Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Grazoprevir (GZR), a direct‐acting agent for hepatitis C virus, is recognized as a substrate for organic anion transporting polypeptide 1B (OATP1B), cytochrome P450 3A (CYP3A), and P‐glycoprotein (P‐gp). The objective of the present study was to elucidate the contribution of these molecules to the nonlinear pharmacokinetics of GZR using a physiologically based pharmacokinetic (PBPK) model. Utilizing plasma concentration–time profiles of GZR derived from reported dose‐escalation (50–800 mg) clinical studies and cumulative excretion data, around 10 parameters, including Michaelis constants (K m ) for OATP1B, CYP3A, and P‐gp, were estimated via a cluster Gauss–Newton method (CGNM). Parameter combinations that could reproduce the clinical data of GZR were obtained; however, discrepancies were noted between the in vivo estimated K m and the corresponding in vitro K m . Next, by incorporating the in vitro K m values into our PBPK–CGNM analyses utilizing a penalized parameter method, newly obtained parameter combinations appropriately reflected both the in vivo and in vitro observations. Particularly regarding OATP1B, while saturation of uptake was not clearly observed in the in vitro experiments without human serum albumin (HSA), K m values capable of explaining in vivo saturation were obtained under physiological HSA concentrations. By estimating the extent of saturation for each molecule in the liver and intestine and conducting sensitivity analyses of the K m values, it was inferred that OATP1B3 contributed the most to the nonlinearity of plasma GZR concentrations, followed by P‐gp. In conclusion, the PBPK–CGNM, supplemented by penalized in vitro parameters, was shown to be effective for analyzing complex pharmacokinetics involving drug transporters and enzymes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Models, BiologicalATP Binding Cassette Transporter, Subfamily B, Member 1Cytochrome P-450 CYP3AAntiviral AgentsQuinoxalinesHumansAmidesLiver-Specific Organic Anion Transporter 1CyclopropanesCarbamatesSulfonamidesNonlinear DynamicsLactams, Macrocyclic

Stichwörter der Autor:innen

CYP3AMichaelis constantOATP1BPBPK modelingP‐gpmiddle‐out approachnonlinear pharmacokinetics

Substanzen

ATP Binding Cassette Transporter, Subfamily B, Member 1AmidesgrazoprevirCytochrome P-450 CYP3ALiver-Specific Organic Anion Transporter 1CyclopropanesAntiviral AgentsCarbamatesQuinoxalinesSulfonamides

Autor:innen und Institutionen

  • Laboratory of Clinical Pharmacology, Yokohama University of Pharmacy, Yokohama, Kanagawa, Japan.
  • Laboratory of Quantitative System Pharmacokinetics/Pharmacodynamics, School of Pharmacy, Josai International University, Tokyo, Japan.
  • Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • iHuman Institute, ShanghaiTech University, Shanghai, China.

ORCID-Profile: Takashi Yoshikado, Yasunori Aoki, Koji Chiba

Zitieren

APA

Yoshikado, T., Aoki, Y., Nakamura, R., Shida, S., Sugiyama, Y., & Chiba, K. (2025). Elucidating Contributions of Drug Transporters/Enzyme to Nonlinear Pharmacokinetics of Grazoprevir by PBPK Modeling With a Cluster Gauss–Newton Method. CPT: Pharmacometrics & Systems Pharmacology, 14(4), 770-780. https://doi.org/10.1002/psp4.13314

Vancouver

Yoshikado T, Aoki Y, Nakamura R, Shida S, Sugiyama Y, Chiba K. Elucidating Contributions of Drug Transporters/Enzyme to Nonlinear Pharmacokinetics of Grazoprevir by PBPK Modeling With a Cluster Gauss–Newton Method. CPT: Pharmacometrics & Systems Pharmacology. 2025;14(4):770-780. doi:10.1002/psp4.13314

BibTeX
@article{Yoshikado2025,
  author = {Yoshikado, Takashi and Aoki, Yasunori and Nakamura, Ryo and Shida, Saeko and Sugiyama, Yuichi and Chiba, Koji},
  title = {Elucidating Contributions of Drug Transporters/Enzyme to Nonlinear Pharmacokinetics of Grazoprevir by PBPK Modeling With a Cluster Gauss–Newton Method},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2025},
  volume = {14},
  number = {4},
  pages = {770--780},
  doi = {10.1002/psp4.13314}
}
Kostenlos starten →